Product Name:
Fgr-ANT
Product Number:
ab-nk268-1
Target Full Name: Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene
Target Alias: C-Fgr; Fgr protein; Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene; Kinase Fgr; P55c-fgr; P55-Fgr; p58c-fgr; Proto-oncogene tyrosine-protein kinase Fgr; SRC2; FLJ43153; MGC75096; Q5TGY6; ENSG00000000938
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK268-1
Antibody Target Type: Pan-specific
Protein UniProt: P09769
Protein SigNET: P09769
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Fgr sequence peptide Cat. No.: PE-01BCW90
Antibody Immunogen Sequence: CKKLEPVATAKEDAGLEGDF
Antibody Immunogen Description: Corresponds to amino acid residues C6 to F25; Post-N-terminus
Production Method: Corresponds to amino acid residues C6 to F25; Post-N-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1.0 / 0.45 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 55-63 kDa.
Related Product 1: Fgr-ANT blocking peptide
Related Product 2: Fgr-pY208+pY209 phosphosite-specific antibody (Cat. No.: AB-PK638)
Related Product 3: Fgr-pY412 phosphosite-specific antibody (Cat. No.: AB-PK639)
Scientific Background: Fgr is a protein-tyrosine kinase of the TK group and Src family. It is a non-receptor kinase that transmits signals from cell surface receptors and regulates immune responses. In addition, it functions as positive regulator of cell migration and regulates cytoskeleton reorganization. Fgr appears to be an oncoprotein (OP). A Y523F mutation in Fgr is associated with strongly increased catalytic activity, which can be oncogenic and promote abnormal cell proliferation. Fgr oncogene mRNA was found to be induced in B lymphocytes by Epstein-Barr virus infection.